Effectiveness of insecticide-impregnated dog collars in reducing incidence rate of canine visceral leishmaniasis: A systematic review and meta-analysis

ObjectiveWe performed a systematic review and meta-analysis of epidemiological data of injuries in professional male football.MethodForty-four studies have reported the incidence of injuries in football. Two reviewers independently extracted data and assessed trial quality using the Strengthening the Reporting of Observational Studies in Epidemiology statement and Newcastle Ottawa Scale. Studies were combined in a pooled analysis using a Poisson random effects regression model.ResultsThe overall incidence of injuries in professional male football players was 8.1 injuries/1000 hours of exposure. Match injury incidence (36 injuries/1000 hours of exposure) was almost 10 times higher than training injury incidence rate (3.7 injuries/1000 hours of exposure). Lower extremity injuries had the highest incidence rates (6.8 injuries/1000 hours of exposure). The most common types of injuries were muscle/tendon (4.6 injuries/1000 hours of exposure), which were frequently associated with traumatic incidents. Minor injuries (1–3 days of time loss) were the most common. The incidence rate of injuries in the top 5 European professional leagues was not different to that of the professional leagues in other countries (6.8 vs 7.6 injuries/1000 hours of exposure, respectively).ConclusionsProfessional male football players have a substantial risk of sustaining injuries, especially during matches.

Download Full-text

Prevalence estimates of human immunodeficiency virus (HIV) infection among visceral leishmaniasis infected people in Northwest Ethiopia: a systematic review and meta-analysis

BMC Infectious Diseases ◽

10.1186/s12879-020-4935-x ◽

2020 ◽

Vol 20 (1) ◽

Cited By ~ 2

Author(s):

Mehdi Mohebali ◽

Yonas Yimam

Keyword(s):

Systematic Review ◽

Human Immunodeficiency Virus ◽

Visceral Leishmaniasis ◽

Hiv Infection ◽

Meta Analysis ◽

Northwest Ethiopia ◽

Infected People ◽

Immunodeficiency Virus ◽

Prevalence Estimates

Download Full-text

Incidence rate and clinical impacts of arrhythmia following COVID-19: a systematic review and meta-analysis of 17,435 patients

Critical Care ◽

10.1186/s13054-020-03368-6 ◽

2020 ◽

Vol 24 (1) ◽

Author(s):

Shu-Chen Liao ◽

Shih-Chieh Shao ◽

Chi-Wen Cheng ◽

Yung-Chang Chen ◽

Ming-Jui Hung

Keyword(s):

Systematic Review ◽

Incidence Rate ◽

Meta Analysis

Download Full-text

Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.6_suppl.398 ◽

2013 ◽

Vol 31 (6_suppl) ◽

pp. 398-398 ◽

Cited By ~ 1

Author(s):

Shanthi Sivendran ◽

Jian Ying ◽

Benjamin Adam Gartrell ◽

Neeraj Agarwal ◽

Kenneth M. Boucher ◽

...

Keyword(s):

Systematic Review ◽

Clinical Trials ◽

Adverse Events ◽

Incidence Rate ◽

Meta Analysis ◽

Mtor Inhibitors ◽

Incidence Rates ◽

Metabolic Complications ◽

Randomized Controlled Clinical Trials ◽

Grade 3

398 Background: mTOR inhibitors are approved in several malignancies including renal cell carcinoma (RCC). The risk of metabolic complications with these agents is not well characterized. Methods: PubMed was searched for articles published from 2001 until 2011. Eligible studies included prospective randomized trials evaluating temsirolimus, everolimus, and ridaforolimus in patients with all solid tumor malignancies. 16 eligible phase II clinical trials and 8 randomized controlled clinical trials were included in a systematic review and meta-analysis and the number of metabolic related AEs including hyperglycemia, hypercholesterolemia, and hypertriglyceridemia were extracted. Incidence rates and incident rate ratios were calculated. Results: In total, 24 trials (including 4,261 patients) were included. The average incidence rate of any grade metabolic adverse events and grade 3-4 metabolic adverse events was 0.70 per patient and 0.11 (95% CI, 0.08, 0.15) per patient respectively. Analysis of the 3,317 patients across 8 RCT’s revealed that the log incidence rate ratio (IRR) of any grade metabolic adverse events with mTOR inhibitor therapy compared with control was 1.08 (95% CI, 0.84, 1.31) using a random-effects model. The risk of grade 3-4 adverse events was also increased with an IRR of 1.52 (95% CI, 1.05, 1.99). The IRR of all grade hyperglycemia was 1.08 (95% CI, 0.76, 1.40) and of grade 3-4 hyperglycemia was 1.66 (95% CI, 1.12, 2.20). The IRR of all grade hypertriglyceridemia was 0.91 (95% CI, 0.56, 1.26) and of grade 3-4 hypertriglyceridemia was 0.70 (95% CI,- 0.43, 1.83). The IRR of all grade hypercholesterolemia was 1.21 (95% CI, 0.77, 1.65) and of grade 3-4 hypercholesterolemia was 1.21 (95% CI, 0.77, 1.65). These findings suggest a statistically significant increase in the risk of hyperglycemia, hypercholesterolemia (all grades and grade 3 and 4), and all grade hypertriglyceridemia associated with mTOR therapy when compared with control. Conclusions: The risk of all grade and grade 3-4 metabolic adverse events are increased in patients treated with mTOR inhibitors compared with control. However, grade 3-4 metabolic adverse events remain relatively uncommon.

Download Full-text